Advanced Search

per page
  Report Title Date Provider Type Pgs Price

DURECT Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

02 Oct 2015 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - DURECT Corp (DRRX-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

08 Oct 2015 Thomson Reuters Stock Report 11 $25.00

DRRX: Due Diligence Review: Forensic Earnings and Valuation

Reports provide superior value and incorporate critical data from the Financial Footnotes and MD&A that other firms miss. The...

08 Oct 2015 New Constructs, LLC 10 $25.00

ValuEngine Rating and Forecast Report for DRRX

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

04 Oct 2015 ValuEngine, Inc. 11 $25.00

Value Graph: DURECT -- DRRX

02 Oct 2015 Ford Investor Services, Inc. 1 $12.00

Durect Corporation (DRRX, Buy, $4 PT) DRRX owns two late stage assets at a significant discount

We recently spent time with the management of DRRX and we come away incrementally more positive on the name as the company is...

30 Sep 2015 Laidlaw & Company 9 $25.00

Wright Investors Service Comprehensive Report for Durect Corporation

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

23 Sep 2015 Wright Reports 56 $75.00

DURECT Corporation (DRRX) - Financial and Strategic SWOT Analysis Review

DURECT Corporation (DRRX) - Financial and Strategic SWOT Analysis Review Summary DURECT Corporation (Durect) is a specialty p...

15 Sep 2015 GlobalData 67 $125.00

Is DURECT Corporation a Good Buy?

14 Sep 2015 Sadif Analytics Prime 12 $25.00

Durect Corporation (DRRX - $2.10) Initiation of Coverage – Lately It Occurs to Me What a Long, Strange Trip It’s Been

We are initiating coverage of Durect (DRRX) with a BUY rating and a $4 price target. DRRX’s main development drug is Remoxy, ...

31 Aug 2015 Laidlaw & Company 25 $75.00